[Objectives]This study was conducted to explore the mechanism of Ganlu Yin in the treatment of COVID-19 based on network pharmacology and molecular docking technology. [Methods] TCMSP, ETCM and TCMID databases were us...[Objectives]This study was conducted to explore the mechanism of Ganlu Yin in the treatment of COVID-19 based on network pharmacology and molecular docking technology. [Methods] TCMSP, ETCM and TCMID databases were used to dig out the chemical components in the compound ingredients of Ganlu Yin. Swiss ADME platform was used for ADME screening and Swiss Target Prediction server was used to predict potential targets of chemical components. The COVID-19 related genes were obtained from GeneCards database and Drugbank website, and the intersection targets between Ganlu Yin and COVID-19 were obtained by Venn analysis. The targets were imported into String analysis platform to construct a protein interaction network, and Cytoscape 3.9.0 software was used for visualization processing. GO enrichment and KEGG pathway analysis were performed on the intersection targets through David database. The core components, clinical antiviral drugs, core targets and novel Coronavirus(SARS-COV-2) hydrolase 3 CLpro(Mpro), omicron B.1.1.529 spike protein and angiotensin converting enzyme 2(ACE2) were tested by molecular docking. [Results] A total of 213 effective chemical components and 1 023 drug targets in Ganlu Yin were screened out, including 4 620 COVID-19 related genes and 328 intersection targets. The core components mainly included β-sitosterol, quercetin, and kaherol. The key core targets involved GAPDH, AKT1, TNF, ALB, and EGFR, etc. A total of 241 items were screened by GO functional enrichment, including inflammatory response, protein phosphorylation, positive regulation of gene expression and other biological processes. A total of 85 KEGG pathways were screened out, which were mainly enriched in influenza A, HIF-1 signaling pathway, hepatitis C and other pathways. The results of molecular docking showed that the core chemical components in Ganlu Yin had good binding ability with core targets and disease targets ACE2, 3 CLpro and spike protein, especially kahenol with ACE2, β-sitosterol with 3 CLpro, and quercetin with spike protein. [Conclusions] Prescription Ganlu Yin has the characteristics of multi-component and multi-target action, and can treat COVID-19 through multiple signaling pathways.展开更多
目的探讨益气甘露方治疗2型糖尿病气阴两虚证的临床疗效及其对血清代谢产物的影响。方法将80例2型糖尿病气阴两虚证患者随机分为对照组、试验组,每组40例,同时选取了40名与糖尿病患者年龄、性别相匹配的健康人作为健康对照组。西药对照...目的探讨益气甘露方治疗2型糖尿病气阴两虚证的临床疗效及其对血清代谢产物的影响。方法将80例2型糖尿病气阴两虚证患者随机分为对照组、试验组,每组40例,同时选取了40名与糖尿病患者年龄、性别相匹配的健康人作为健康对照组。西药对照组予二甲双胍治疗,中药试验组予益气甘露方治疗,对比治疗前后两组的临床疗效、生化指标、炎症因子、中医症状积分及血清代谢产物的变化。结果治疗前,两组患者的血糖及血脂指标比较差异无统计学意义(P>0.05);治疗后,两组患者的FPG、2 h PG、HbAlc、INS、INS120′、TC、TG、LDL-C、TNF-α、IL-6、hs-CRP水平与治疗前比较差异均具有统计学意义(P<0.05),且中药试验组疗效不低于西药对照组。2型糖尿病气阴两虚证与健康人的差异性代谢物主要有溶血磷脂酸、磷脂酰乙醇胺、心磷脂、二氢生物蝶呤等,所参与的代谢途径主要涉及脂类代谢和氨基酸代谢。结论益气甘露方可以降低血糖、血脂及炎症水平,调节脂质与氨基酸代谢,改善临床症状。展开更多
文摘[Objectives]This study was conducted to explore the mechanism of Ganlu Yin in the treatment of COVID-19 based on network pharmacology and molecular docking technology. [Methods] TCMSP, ETCM and TCMID databases were used to dig out the chemical components in the compound ingredients of Ganlu Yin. Swiss ADME platform was used for ADME screening and Swiss Target Prediction server was used to predict potential targets of chemical components. The COVID-19 related genes were obtained from GeneCards database and Drugbank website, and the intersection targets between Ganlu Yin and COVID-19 were obtained by Venn analysis. The targets were imported into String analysis platform to construct a protein interaction network, and Cytoscape 3.9.0 software was used for visualization processing. GO enrichment and KEGG pathway analysis were performed on the intersection targets through David database. The core components, clinical antiviral drugs, core targets and novel Coronavirus(SARS-COV-2) hydrolase 3 CLpro(Mpro), omicron B.1.1.529 spike protein and angiotensin converting enzyme 2(ACE2) were tested by molecular docking. [Results] A total of 213 effective chemical components and 1 023 drug targets in Ganlu Yin were screened out, including 4 620 COVID-19 related genes and 328 intersection targets. The core components mainly included β-sitosterol, quercetin, and kaherol. The key core targets involved GAPDH, AKT1, TNF, ALB, and EGFR, etc. A total of 241 items were screened by GO functional enrichment, including inflammatory response, protein phosphorylation, positive regulation of gene expression and other biological processes. A total of 85 KEGG pathways were screened out, which were mainly enriched in influenza A, HIF-1 signaling pathway, hepatitis C and other pathways. The results of molecular docking showed that the core chemical components in Ganlu Yin had good binding ability with core targets and disease targets ACE2, 3 CLpro and spike protein, especially kahenol with ACE2, β-sitosterol with 3 CLpro, and quercetin with spike protein. [Conclusions] Prescription Ganlu Yin has the characteristics of multi-component and multi-target action, and can treat COVID-19 through multiple signaling pathways.
文摘目的探讨益气甘露方治疗2型糖尿病气阴两虚证的临床疗效及其对血清代谢产物的影响。方法将80例2型糖尿病气阴两虚证患者随机分为对照组、试验组,每组40例,同时选取了40名与糖尿病患者年龄、性别相匹配的健康人作为健康对照组。西药对照组予二甲双胍治疗,中药试验组予益气甘露方治疗,对比治疗前后两组的临床疗效、生化指标、炎症因子、中医症状积分及血清代谢产物的变化。结果治疗前,两组患者的血糖及血脂指标比较差异无统计学意义(P>0.05);治疗后,两组患者的FPG、2 h PG、HbAlc、INS、INS120′、TC、TG、LDL-C、TNF-α、IL-6、hs-CRP水平与治疗前比较差异均具有统计学意义(P<0.05),且中药试验组疗效不低于西药对照组。2型糖尿病气阴两虚证与健康人的差异性代谢物主要有溶血磷脂酸、磷脂酰乙醇胺、心磷脂、二氢生物蝶呤等,所参与的代谢途径主要涉及脂类代谢和氨基酸代谢。结论益气甘露方可以降低血糖、血脂及炎症水平,调节脂质与氨基酸代谢,改善临床症状。
